What is the Wolverine Stack?

The Wolverine stack is an industry nickname for pairing two unrelated synthetic research peptides, BPC-157 and TB-500, in one preparation. It names a combination, not a molecule, a brand or a registered formulation, and it does not appear in the research literature. Everything that can be said about it scientifically is said about its two components, which have separate chemistry, separate bodies of research and, as of September 2026, almost no published work examining them together. We supply the pairing as the Wolverine Stack: 10mg of each, 20mg in total, pre-mixed in one vial with a batch certificate.

Research use only. This guide covers the identity, chemistry and published literature of BPC-157 and TB-500 as laboratory materials. It does not describe dosing or administration, makes no therapeutic claims, and does not address use in people or animals.

Where the name comes from, and what it leaves open

"Wolverine" is borrowed from a comic-book character, and the connotation is a marketing one: a PubMed title-and-abstract search pairing "Wolverine" with "peptide" returned no records on 12 September 2026. The pairing is also sold as Wolverine peptide, the Wolverine blend or plain BPC-157 + TB-500, and in peptide retail a "stack" can mean two separate vials sold as a set as easily as two peptides in one vial.

Because nobody defines the term, it fixes only the two compound names. It does not fix:

• The mass of each component, and so the ratio between them
• The total mass in the vial
• The physical form: separate vials, a mixed freeze-dried powder, or a solution
• Which molecule "TB-500" refers to, which matters more than any of the above

The composition stated on a batch certificate is what identifies the material.

The two molecules, and the one they get confused with

BPC-157. The letters stand for "body protection compound", and the sequence derives from a protein found in human gastric juice. It is a linear chain with free ends and no modified residues. Two features stand out: four of its fifteen residues are proline, three of them in an unbroken run near the N-terminus, which limits how freely the backbone can fold; and three acidic side chains (two aspartates and a glutamate) against a single lysine give it a net negative charge at neutral pH. The BPC-157 guide covers it on its own.

TB-500. The name began as a product name rather than a chemical one. The doping control laboratory at Ghent University identified the seven-residue peptide Leu-Lys-Lys-Thr-Glu-Thr-Gln, with an acetyl group on its N-terminus, in a TB-500 product (Esposito et al., 2012), and a racing laboratory described TB-500 as a veterinary preparation whose key ingredient is that peptide (Ho et al., 2012). That sequence is residues 17–23 of human thymosin beta-4; the acetyl cap is an addition, since inside the intact protein that leucine is bonded to the residue before it. The fragment has no aromatic residues, and its two lysines balance its glutamate and free C-terminal carboxyl, leaving it close to neutral at pH 7.

Thymosin beta-4 is the parent protein: 43 residues, acetylated at its N-terminal serine, and present at high concentrations in almost every cell. The table breaks its sequence around residues 17–23, shown in bold, which are the part TB-500 is taken from. TB-500 is less than a fifth of its mass. Sellers use the two names interchangeably, so a label alone does not tell you which molecule is in a vial; the molecular mass on a certificate does, and the TB-500 guide covers the naming problem in detail.

Why the fragment is not the protein

Thymosin beta-4 earned its place in cell biology through actin. In 1991 a University of Pennsylvania group sequenced an actin-sequestering peptide from human platelets and found it identical to thymosin beta-4, a protein first isolated from calf thymus and then thought to be a thymic hormone. The protein binds actin monomers (G-actin) in a one-to-one complex and, while bound, inhibits their polymerisation into filaments (Safer et al., 1991). A 2001 overview of the β-thymosin family describes these proteins as the main intracellular G-actin-sequestering peptides, acting as buffers that hold back a pool of monomers until a cell needs filaments (Huff et al., 2001).

The question for anyone reading about TB-500 is how much of that behaviour belongs to residues 17–23. A 1996 mutational study built synthetic full-length variants to map the actin-binding site and found two separate structural elements taking part: an N-terminal region, residues 1–16, that needs to adopt an α-helix to bind, and a hexapeptide motif at residues 17–22 (Van Troys et al., 1996). TB-500 contains the motif. It does not contain the N-terminal helix.

That is the chemical reason a thymosin beta-4 paper is not a TB-500 paper. Some TB-500 papers call residues 17–23 the protein's actin-binding site (Ho et al., 2012), and a handful of primary studies do test the fragment itself, but the protein's actin interaction was characterised with both elements present, and findings about it do not carry over to a fragment containing only one of them unless the fragment itself is tested. The same 2001 overview also noted that, at that time, no molecular mechanism had been established for the effects attributed to extracellular beta-thymosins.

What each literature actually examines

The two components have separate literatures of very different shapes. The counts below come from PubMed title-and-abstract searches run on 12 September 2026; they are approximate, but the proportions are the point.

BPC-157: mostly preclinical, mostly one group

A search for BPC-157 returns 223 records. Of those, 174, about 78%, include the same senior investigator among their authors, whose group is based at the University of Zagreb School of Medicine. Concentrated authorship says nothing by itself about any single study, but it does mean independent replication is thinner than the headline count suggests.

A 2025 systematic review in the HSS Journal identified 544 articles published between 1993 and mid-2024 and included 36 studies: 35 preclinical and a single clinical report. It catalogued mechanistic work on growth hormone receptor expression and on pathways associated with cell growth and angiogenesis, found no clinical safety data, and noted that the compound lacks US regulatory approval and is banned in professional sport (Vasireddi et al., 2025).

At the cell-culture end of that literature, Chang and colleagues isolated fibroblasts from rat Achilles tendon, screened gene expression by cDNA microarray after exposure to BPC-157, then measured growth hormone receptor at mRNA and protein level and followed downstream Janus kinase 2 signalling after growth hormone was added (Chang et al., 2014). It is one cell type, from one species, under defined culture conditions: informative about a pathway in that system, not evidence about a whole organism.

TB-500: a small literature, much of it analytical

Thymosin beta-4 returns more than 1,100 records. TB-500, searched by name or by its sequence, returns 36, of which about 28 concern the peptide once unrelated matches are removed: roughly half analytical or anti-doping papers, a quarter literature overviews and a quarter primary studies. The names are also blurred in the literature: a 2026 scoping review groups "thymosin beta-4 or TB-500" as one entry (Tewari et al., 2026), so a statement about what "TB-500" does in secondary writing can rest on work with the full protein.

The largest share of the fragment-specific work is anti-doping chemistry rather than biology. In 2012 the doping control laboratory at Ghent University identified Ac-LKKTETQ in a TB-500 product by high-resolution mass spectrometry, synthesised the peptide by solid-phase synthesis and proposed a detection method for plasma and urine (Esposito et al., 2012). The same year, the Hong Kong Jockey Club's racing laboratory published a method for detecting the acetylated peptide and its metabolites in equine urine and plasma (Ho et al., 2012). Those papers are the best available sources on what TB-500 is chemically. They are not studies of what it does.

Where the two meet: close to nothing

A search for records that mention BPC-157 together with a thymosin term or TB-500 returns 11. Eight are literature overviews of peptides in sports, orthopaedic and other clinical fields that discuss the two side by side. One is an anti-doping analytical method listing both among dozens of target analytes. One is a small uncontrolled retrospective report. One is a controlled experiment.

That experiment, published in July 2026, used a surgical Achilles-tendon model in 32 rats divided into four groups of eight: a control group, BPC-157 alone, TB-500 alone, and the two combined. Tissue was assessed at four weeks by biomechanical load-to-failure testing, histological scoring, and immunohistochemistry for collagen types I and III, and the authors describe the work as exploratory (Biçer et al., 2026). It also shows the naming problem: the paper identifies its TB-500 only as a commercially sourced synthetic peptide derived from thymosin beta-4 and reports no sequence or mass, so it is not confirmed that the seven-residue fragment was the material tested. One small rodent study is not a literature.

Two recent critical overviews frame the rest. A 2026 scoping review in The American Journal of Sports Medicine, covering six emerging peptides including BPC-157 and thymosin beta-4/TB-500, found that two-thirds of the publications it identified used preclinical animal models, that human studies were few and mostly lacked robust controls or rigorous designs, and that the marketing claims made for these peptides in sports medicine remain unsubstantiated by current human trials (Tewari et al., 2026). A 2026 narrative overview in Sports Medicine lists thymosin beta-4 and TB-500 as separate entries and notes that rigorous human safety data are scarce (Mendias and Awan, 2026).

Anything said about "the Wolverine stack" as a unit is therefore an inference assembled from two separate literatures, one largely preclinical and concentrated in a single group, the other largely about a different, much larger molecule.

Why the two are paired at all

The case for studying them together is one of experimental design, not an established property of the pair. The molecules are chemically unrelated, and the mechanisms examined for them sit in different places: receptor expression and signalling for BPC-157, actin binding and cytoskeletal organisation for thymosin beta-4, the protein TB-500 is taken from. The limitation runs the other way: a combined preparation cannot tell you which component produced an observation, so work on the pair needs single-compound arms alongside it. BPC-157 vs TB-500 compares the two directly.

Reading a certificate of analysis for a two-component vial

A single-compound certificate answers two questions: is this the right molecule, and how much of the material is that molecule. A two-component certificate has to answer both twice. The general format is covered in what a Certificate of Analysis is; these points are specific to this pairing.

Identity: two masses, and which TB-500. Mass spectrometry should show the expected mass for each component. Electrospray instruments usually report protonated ions and monoisotopic values rather than the average molecular weights in the table above, so the figures to look for differ slightly:

A mass near 4,960 Da where TB-500 should be describes full-length thymosin beta-4, not the fragment: a different material sold under the same label.

Purity: per component, not per vial. HPLC purity is a peak-area percentage, the share of the detected material that elutes as the target peptide. A mixture has two target peaks, and a single "99%" for the whole vial does not say which peak it refers to or how the two are split. Look for a purity figure attached to each compound. Ours are certified individually, and recent certificates are in the COA library.

Detection wavelength. Neither sequence contains an aromatic amino acid (no tryptophan, tyrosine or phenylalanine), so neither absorbs usefully at 280 nm. Both are detected in the low-UV range, typically around 210–220 nm, where the peptide bond itself absorbs. A method stated at 280 nm for this pair is worth a question.

Purity is not content. Peak-area purity says nothing about how many milligrams are present. A freeze-dried peptide can be high-purity and still carry part of its weight as counter-ions and water; for a solution, the figure that matters is the concentration of each component.

The split. Equal milligrams are not equal numbers of molecules: a TB-500 molecule weighs less than two-thirds as much as a BPC-157 molecule. The Wolverine Stack product page works through the molar arithmetic.

The basics still apply. A batch number that matches the vial in front of you, a test date, and the analytical method named for each result.

Why a pre-mixed solution matters more for a pair

Where this pairing is supplied as a freeze-dried powder, it has to be dissolved at the bench, and with two peptides of different size and charge in one vial, the liquid holds the labelled ratio only if both dissolve fully.

A solution prepared and documented as a batch fixes the ratio when the batch is made, and the certificate describes the liquid actually in the vial. The trade-off is the cold chain: ours ships chilled and is kept at 2–8°C, never frozen. How to store research peptides covers handling.

What the Wolverine stack is not

• Not an approved medicine. Neither BPC-157 nor TB-500 is licensed as a medicine in the UK or elsewhere, and neither is supplied here for human or veterinary use.
• Not a standardised product. Two suppliers' vials under the same nickname can differ in ratio, total, form and molecule.
• Not thymosin beta-4. TB-500 is a seven-residue fragment of it.
• Not a characterised combination. Controlled published work on the pair is one small exploratory rodent study with a combined group, and nothing in the literature defines the pair as a unit.
• Not permitted in competitive sport. Both compounds are listed as prohibited by the World Anti-Doping Agency (WADA); the TB-500 guide covers the detail.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for the Wolverine stack or either of its components. The material is supplied only for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person or an animal would be inconsistent with what is actually supplied.

How it is supplied

The Wolverine Stack is supplied as a pre-mixed 20mg vial, BPC-157 10mg and TB-500 10mg, with a batch-specific Certificate of Analysis, dispatched from our UK facility under cold-chain handling and stored refrigerated at 2–8°C.

The components are available individually as BPC-157 and TB-500. The same pair also forms the base of two wider sets: the Glow Stack adds GHK-Cu, and the Klow Stack includes both GHK-Cu and KPV.

Related reading

• What is BPC-157?
• What is TB-500?
• BPC-157 vs TB-500
• What is Glow peptide?
• What is a Certificate of Analysis?